HENDERSON, NV / ACCESSWIRE / July 25, 2016 / Rainbow Coral Corp. (OTCQB: RBCC) partner company n3D has just inked a groundbreaking agreement with a leading preclinical contract research organization (CRO) to screen promising compound cancer via its revolutionary magnetic 3D bioprinting technology. The deal greatly expands n3D's market reach and solidifies the company's position as a potential leader in the bioprinting field.

SBH Biosciences (SBH) will use n3D's cutting-edge bioprinting technology to make rapid and high-throughput lead optimization tests (or assays) for compounds that will target often difficult oncology pathways. In addition to the cancer drug testing aspect, SBH will also offer n3D's wound-healing assay model in its wide portfolio of tests as part of the venture.

"This is a very exciting arrangement with solid long-term prospects for n3D and our partner RBCC," said n3D President and Chief Science Officer Glauco Souza. "We've broadened our already strong market presence and shown n3D's life sciences technology leads the pack in the drug discovery, testing and development field. With this landmark agreement now in place, n3D is well positioned for further advances."

RBCC CEO Kimberly Palmer hailed the new n3D/SBH deal. "n3D continues to show why it's a well-respected innovator in the magnetic 3D printing market," Palmer said. "Word has spread that the company has unique, forward-looking solutions that can help doctors and scientists solve the many medical problems facing the world today. We're proud to be a partner with n3D and we can't wait to see what the future holds for this agreement and the others sure to come."

RBCC partner n3D most recently had a well-regarded article on magnetic 3D bioprinting published on a respected medical technology company's website, garnering valuable publicity and prestige.

For more information on RBCC's initiatives, please visit www.rainbowbiocorp.com.

About Rainbow Biosciences

Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.rainbowbiocorp.com.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Contact:

Rainbow Coral Corp.
Kimberly Palmer, 702-940-2345
President and CEO
info@rainbowcoral.com

SOURCE: Rainbow Coral Corp.